skip to main content
Idioma:
Resultados 1 2 3 4 next page
Refinado por: Nome da Publicação: Cancer Research remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Abstract P1-07-08: Young age and the risk of disease recurrence as assessed by the 70-gene signature – an analysis from the EORTC 10041/BIG 03-04 MINDACT trial
Abstract P1-07-08: Young age and the risk of disease recurrence as assessed by the 70-gene signature – an analysis from the EORTC 10041/BIG 03-04 MINDACT trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Abstract P1-07-08: Young age and the risk of disease recurrence as assessed by the 70-gene signature – an analysis from the EORTC 10041/BIG 03-04 MINDACT trial

Aalders, K ; Genbrugge, E ; Poncet, C ; Kuijer, A ; Pistilli, B ; Piccart, M ; Tryfonidis, K ; van Dalen, T ; Cardoso, F ; van 't Veer, L ; Rutgers, E

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P1-P1-07-08 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
2
Abstract P1-07-02: Withdrawn
Abstract P1-07-02: Withdrawn
Material Type:
Artigo 		Adicionar ao Meu Espaço

Abstract P1-07-02: Withdrawn

Rutgers, E ; Aalders, K ; Poncet, C ; Bogaerts, J ; Delaloge, S ; Rubio, I ; Thompson, A ; Tryfonidis, K ; van 't Veer, L ; Piccart, M ; Cardoso, F

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P1-P1-07-02 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
3
Abstract PD3-09: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2- positive metastatic breast cancer: Results from the EORTC 75111- 10114 ETF/BCG randomized phase II study
Abstract PD3-09: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2- positive metastatic breast cancer: Results from the EORTC 75111- 10114 ETF/BCG randomized phase II study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Abstract PD3-09: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2- positive metastatic breast cancer: Results from the EORTC 75111- 10114 ETF/BCG randomized phase II study

Wildiers, H ; Tryfonidis, K ; dal Lago, L ; Vuylsteke, P ; Curigliano, G ; Waters, S ; Brouwers, B ; Aalders, K ; Meulemans, B ; Litiere, S ; Touati, N ; Cardoso, F ; Brain, E

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.PD3-09-PD3-09 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
4
Abstract P1-15-16: Pathological complete response rates with the addition of carboplatin to standard neoadjuvant chemotherapy in a cohort of real–world patients with triple negative breast cancer
Abstract P1-15-16: Pathological complete response rates with the addition of carboplatin to standard neoadjuvant chemotherapy in a cohort of real–world patients with triple negative breast cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

Abstract P1-15-16: Pathological complete response rates with the addition of carboplatin to standard neoadjuvant chemotherapy in a cohort of real–world patients with triple negative breast cancer

Ramalho, S ; Natal, RdA ; Cardoso Filho, C ; Xavier, MB ; da Silva, AER ; Silva, LR ; Vasconcelos, V ; Reinert, T ; Coelho, GP ; Silva, GRdP ; dos Santos, CC

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P1-P1-15-16 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
5
Abstract OT3-04-03: KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab versus placebo in combination with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk early-stage ER+/HER2– breast cancer
Abstract OT3-04-03: KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab versus placebo in combination with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk early-stage ER+/HER2– breast cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

Abstract OT3-04-03: KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab versus placebo in combination with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk early-stage ER+/HER2– breast cancer

Cardoso, F ; Bardia, A ; Andre, F ; Cescon, DW ; McArthur, H ; Telli, M ; Loi, S ; Cortés, J ; Schmid, P ; Harbeck, N ; Denkert, C ; Jackisch, C ; Jia, L ; Tryfonidis, K ; Karantza, V

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.OT3-04-03-OT3-04-03 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
6
Abstract PD7-01: Can surrogate pathological subtyping replace molecular subtyping? Outcome results from the MINDACT trial
Abstract PD7-01: Can surrogate pathological subtyping replace molecular subtyping? Outcome results from the MINDACT trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Abstract PD7-01: Can surrogate pathological subtyping replace molecular subtyping? Outcome results from the MINDACT trial

Cardoso, F ; Slaets, L ; de Snoo, F ; Bogaerts, J ; van 't Veer, LJ ; Rutgers, EJ ; Piccart-Gebhart, MJ ; Stork-Sloots, L ; Russo, L ; Dell'Orto, P ; Viale, G

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.PD7-01-PD7-01 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
7
Abstract PS12-17: Baseline characteristics of women enrolled in the POSITIVE trial (pregnancy outcome and safety of interrupting therapy for women with endocrine responsIVE breast cancer)
Abstract PS12-17: Baseline characteristics of women enrolled in the POSITIVE trial (pregnancy outcome and safety of interrupting therapy for women with endocrine responsIVE breast cancer)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Abstract PS12-17: Baseline characteristics of women enrolled in the POSITIVE trial (pregnancy outcome and safety of interrupting therapy for women with endocrine responsIVE breast cancer)

Partridge, Ann H ; Niman, Samuel M ; Ruggeri, Monica ; Peccatori, Fedro A ; Azim, Hatem A ; Colleoni, Marco ; Saura, Cristina ; Shimizu, Chikako ; Sætersdal, Anna Barbro ; Kroep, Judith ; Warner, Ellen ; Borges, Virginia F ; Gombos, Andrea ; Kataoka, Akemi ; Rousset-Jablonski, Christine ; Borstnar, Simona ; Yamauchi, Hideko ; Lee, Jeong Eon ; Walshe, Janice M ; Borrego, Manuel Ruíz ; Moore, Halle CF ; Saunders, Christobel ; Cardoso, Fatima ; Susnjar, Snezana ; Bjelic-Radisic, Vesna ; Smith, Karen L ; Piccart, Martine ; Korde, Larissa A ; Goldhirsch, Aron ; Gelber, Richard D ; Pagani, Olivia

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS12-17-PS12-17 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
8
Abstract P4-12-01: MammaPrint is cost-effective compared to clinical risk assessment in early stage breast cancer
Abstract P4-12-01: MammaPrint is cost-effective compared to clinical risk assessment in early stage breast cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

Abstract P4-12-01: MammaPrint is cost-effective compared to clinical risk assessment in early stage breast cancer

Retèl, VP ; Joore, MA ; van 't Veer, LJ ; Cardoso, F ; Piccart, MJ ; Rutgers, EJ ; Tryfonidis, K ; Poncet, C ; van Harten, WH

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P4-P4-12-01 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
9
Abstract P6-19-01: Evaluation of multiple transcriptomic gene risk signatures in male breast cancer
Abstract P6-19-01: Evaluation of multiple transcriptomic gene risk signatures in male breast cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

Abstract P6-19-01: Evaluation of multiple transcriptomic gene risk signatures in male breast cancer

Bayani, J ; Poncet, C ; Yao, CQ ; Crozier, C ; Anouk, N ; Piper, T ; Cunningham, C ; Sobol, M ; Aebi, S ; Benstead, K ; Bogler, O ; Dal Lago, L ; Fraser, J ; Hilbers, FH ; Hedenfalk, I ; Korde, L ; Linderholm, B ; Martens, J ; Middleton, L ; Murray, M ; Kelly, C ; Nilsson, C ; Nowaczyk, M ; Peeters, S ; Peric, A ; Porter, P ; Schröder, C ; Rubio, IT ; Ruddy, KJ ; van Asperen, C ; Van Den Weyngaert, D ; van Deurzen, C ; van Leeuwen-Stok, E ; Vermeij, J ; Winer, E ; Boutros, PC ; Giordano, SH ; Cardoso, F ; Bartlett, JM

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P6-P6-19-01 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
10
Abstract PD7-12: Molecular subtyping of male breast cancer by the International male breast cancer program (IMBC): EORTC 10085/TBCRC 0-29/BIG 2-07/NABCG/BOOG 2009-04
Abstract PD7-12: Molecular subtyping of male breast cancer by the International male breast cancer program (IMBC): EORTC 10085/TBCRC 0-29/BIG 2-07/NABCG/BOOG 2009-04
Material Type:
Artigo 		Adicionar ao Meu Espaço

Abstract PD7-12: Molecular subtyping of male breast cancer by the International male breast cancer program (IMBC): EORTC 10085/TBCRC 0-29/BIG 2-07/NABCG/BOOG 2009-04

Martens, JWM ; Sieuwerts, A ; Ponchet, C ; Smid, M ; de Weerd, V ; Slaets, L ; Piper, T ; van Deurzen, CHM ; Schroder, CP ; Stangle, C ; Kloosterman, W ; van Leeuwen-Stok, E ; Nilsson, C ; Vermeij, J ; Peeters, S ; Goulioti, T ; Nowaczyk, M ; Aebi, S ; Rubio, IT ; Kelly, C ; Bayani, J ; Porter, P ; Murray, M ; Hudis, C ; Middleton, L ; Korde, L ; Ruddy, K ; Winer, E ; Bogler, O ; van den Weyngaert, D ; dal Lago, L ; Fraser, J ; Benstead, K ; van Asperen, C ; Linderholm, B ; Hedenfalk, I ; Tryfonidis, K ; Giordano, S ; Bartlett, J ; Cardoso, F

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.PD7-12-PD7-12 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 next page

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.